Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left"></td><td class="align_center">Grade</td><td class="align_center">Number of IrAE</td><td class="align_center">Intervention</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_justify">Hypophysitis</td><td class="align_center">3-4</td><td class="align_center">3</td><td class="align_center">Methylprednisolone</td></tr><tr><td class="align_justify">Maculopapular rash</td><td class="align_center">1-2</td><td class="align_center">4</td><td class="align_center">Steroid local skin application</td></tr><tr><td class="align_justify">Dry skin</td><td class="align_center">2</td><td class="align_center">2</td><td class="align_center">—</td></tr><tr><td class="align_justify">Pruritus</td><td class="align_center">1-2</td><td class="align_center">5</td><td class="align_center">Antihistaminic</td></tr><tr><td class="align_justify">Diarrhea</td><td class="align_center">1-2</td><td class="align_center">7</td><td class="align_center">—</td></tr><tr><td class="align_justify">Colitis</td><td class="align_center">3</td><td class="align_center">4</td><td class="align_center">Methylprednisolone</td></tr><tr><td class="align_justify">Hepatitis</td><td class="align_center">3</td><td class="align_center">1</td><td class="align_center">Methylprednisolone</td></tr><tr><td class="align_justify">Pneumonitis</td><td class="align_center">3</td><td class="align_center">1</td><td class="align_center">Methylprednisolone</td></tr><tr><td class="align_justify">Flu-like syndrome</td><td class="align_center">2</td><td class="align_center">2</td><td class="align_center">—</td></tr><tr><td class="align_justify">Guillain-Barré</td><td class="align_center">4</td><td class="align_center">1</td><td class="align_center">Methylprednisolone</td></tr><tr><td class="align_justify">Sarcoidosis</td><td class="align_center">2</td><td class="align_center">1</td><td class="align_center">Methylprednisolone</td></tr><tr><td class="align_justify">Fatigue</td><td class="align_center">2</td><td class="align_center">4</td><td class="align_center">—</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Overview of immune-related adverse events (IrAEs).</div>

Journal of Immunology Research

tab2

Table 2

Table 2: Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab 

Table 2 | Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab 